Treatment of hypertension during pregnancy : a cohort of pregnancy episodes from the SIDIAP database, Catalonia, Spain
Lestón Vázquez, Marta (Universitat Autònoma de Barcelona)
Gomez-Lumbreras, Ainhoa (University of Utah)
Vilaplana-Carnerero, Carles (Institut Universitari d'Investigació en Atenció Primària Jordi Gol)
Vedia Urgell, Cristina (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia)
Morros, Rosa (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia)
Giner-Soriano, Maria (Institut Universitari d'Investigació en Atenció Primària Jordi Gol)

Data:	2024
Resum:	Introduction: Hypertension during pregnancy is one of the most frequent causes of maternal and fetal morbimortality. Perinatal and maternal death and disability rates have decreased by 30%, but hypertension during pregnancy has increased by approximately 10% in the last 30 years. This research aimed to describe the pharmacological treatment and pregnancy outcomes of pregnancies with hypertension. Methods: We carried out an observational cohort study from the Information System for the Development of Research in Primary Care (SIDIAP) database. Pregnancy episodes with hypertension (ICD-10 codes for hypertension, I10-I15 and O10-O16) were identified. Antihypertensives were classified according to the ATC WHO classification: β-blocking agents (BBs), calcium channel blockers (CCBs), agents acting on the renin-angiotensin system (RAS agents), diuretics, and antiadrenergic agents. Exposure was defined for hypertension in pregnancies with ≥2 prescriptions during the pregnancy episode. Descriptive statistics for diagnoses and treatments were calculated. Results: In total, 4,839 pregnancies with hypertension diagnosis formed the study cohort. There were 1,944 (40. 2%) pregnancies exposed to an antihypertensive medication. There were differences in mother's age, BMI, and alcohol intake between pregnancies exposed to antihypertensive medications and those not exposed. BBs were the most used (n = 1,160 pregnancy episodes; 59. 7%), followed by RAS agents (n = 825, 42. 4%), and CCBs were the least used (n = 347, 17. 8%). Discussion: Pregnancies involving hypertension were exposed to antihypertensive medications, mostly BBs. We conduct a study focused on RAS agent use during pregnancy and its outcomes in the offspring.
Nota:	Altres ajuts: PERIS 2021-2024, modality Research Projects in Primary Care, expedient number SLT/21/000068
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Hypertension ; Pregnancy-induced ; Pregnancy outcome ; Antihypertensive agents ; Cohort studies ; Electronic health records ; EHR
Publicat a:	Frontiers in Pharmacology, Vol. 15 (June 2024) , ISSN 1663-9812

DOI: 10.3389/fphar.2024.1346357
PMID: 38953107

7 p, 1.0 MB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats